E
AnaptysBio, Inc.
ANAB
$18.34
-$0.95-4.93%
E
Sell
12/9/2024Downgrade
AnaptysBio, Inc. (ANAB) was downgraded to E+ from D- on 12/9/2024 due to a decline in the solvency index and valuation index.
AnaptysBio, Inc. (ANAB) was downgraded to E+ from D- on 12/9/2024 due to a decline in the solvency index and valuation index.
D
Sell
12/26/2023Upgraded
AnaptysBio, Inc. (ANAB) was upgraded to D- from E+ on 12/26/2023 due to an increase in the volatility index and growth index. EBIT increased 6.01% from -$40.14M to -$37.73M, and earnings per share increased from -$1.5 to -$1.41.
AnaptysBio, Inc. (ANAB) was upgraded to D- from E+ on 12/26/2023 due to an increase in the volatility index and growth index. EBIT increased 6.01% from -$40.14M to -$37.73M, and earnings per share increased from -$1.5 to -$1.41.
E
Sell
10/25/2023Downgrade
AnaptysBio, Inc. (ANAB) was downgraded to E+ from D- on 10/25/2023 due to a noticeable decline in the total return index, volatility index and solvency index. The quick ratio declined from 12.09 to 10.39.
AnaptysBio, Inc. (ANAB) was downgraded to E+ from D- on 10/25/2023 due to a noticeable decline in the total return index, volatility index and solvency index. The quick ratio declined from 12.09 to 10.39.
D
Sell
3/14/2023Downgrade
AnaptysBio, Inc. (ANAB) was downgraded to D- from D on 3/14/2023 due to a decline in the total return index, solvency index and growth index. The quick ratio declined from 21.09 to 16.99.
AnaptysBio, Inc. (ANAB) was downgraded to D- from D on 3/14/2023 due to a decline in the total return index, solvency index and growth index. The quick ratio declined from 21.09 to 16.99.
D
Sell
5/16/2022Upgraded
AnaptysBio, Inc. (ANAB) was upgraded to D from E+ on 5/16/2022 due to an increase in the volatility index.
AnaptysBio, Inc. (ANAB) was upgraded to D from E+ on 5/16/2022 due to an increase in the volatility index.
E
Sell
5/13/2022Downgrade
AnaptysBio, Inc. (ANAB) was downgraded to E+ from D on 5/13/2022 due to a decline in the solvency index and volatility index. The quick ratio declined from 34.1 to 25.61.
AnaptysBio, Inc. (ANAB) was downgraded to E+ from D on 5/13/2022 due to a decline in the solvency index and volatility index. The quick ratio declined from 34.1 to 25.61.
D
Sell
5/4/2022Upgraded
AnaptysBio, Inc. (ANAB) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index and total return index.
AnaptysBio, Inc. (ANAB) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index and total return index.
E
Sell
5/1/2022Downgrade
AnaptysBio, Inc. (ANAB) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index.
AnaptysBio, Inc. (ANAB) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index.
D
Sell
4/21/2022Upgraded
AnaptysBio, Inc. (ANAB) was upgraded to D from E+ on 04/21/2022.
AnaptysBio, Inc. (ANAB) was upgraded to D from E+ on 04/21/2022.
E
Sell
4/20/2022Downgrade
AnaptysBio, Inc. (ANAB) was downgraded to E+ from D on 4/20/2022 due to a substantial decline in the efficiency index, solvency index and volatility index. Net income declined 388.12% from -$6.67M to -$32.54M, and total capital declined 6.71% from $404.54M to $377.38M.
AnaptysBio, Inc. (ANAB) was downgraded to E+ from D on 4/20/2022 due to a substantial decline in the efficiency index, solvency index and volatility index. Net income declined 388.12% from -$6.67M to -$32.54M, and total capital declined 6.71% from $404.54M to $377.38M.
D
Sell
2/8/2022Downgrade
AnaptysBio, Inc. (ANAB) was downgraded to D from D+ on 2/8/2022 due to a noticeable decline in the total return index.
AnaptysBio, Inc. (ANAB) was downgraded to D from D+ on 2/8/2022 due to a noticeable decline in the total return index.
D
Sell
1/12/2022Upgraded
AnaptysBio, Inc. (ANAB) was upgraded to D+ from D on 1/12/2022 due to an increase in the total return index, valuation index and volatility index.
AnaptysBio, Inc. (ANAB) was upgraded to D+ from D on 1/12/2022 due to an increase in the total return index, valuation index and volatility index.
D
Sell
12/28/2021Downgrade
AnaptysBio, Inc. (ANAB) was downgraded to D from D+ on 12/28/2021 due to a decline in the total return index and valuation index.
AnaptysBio, Inc. (ANAB) was downgraded to D from D+ on 12/28/2021 due to a decline in the total return index and valuation index.
D
Sell
12/13/2021Upgraded
AnaptysBio, Inc. (ANAB) was upgraded to D+ from D on 12/13/2021 due to a significant increase in the total return index, efficiency index and solvency index.
AnaptysBio, Inc. (ANAB) was upgraded to D+ from D on 12/13/2021 due to a significant increase in the total return index, efficiency index and solvency index.
D
Sell
12/23/2020Upgraded
AnaptysBio, Inc. (ANAB) was upgraded to D from D- on 12/23/2020 due to an increase in the total return index, volatility index and valuation index.
AnaptysBio, Inc. (ANAB) was upgraded to D from D- on 12/23/2020 due to an increase in the total return index, volatility index and valuation index.
D
Sell
12/4/2020Downgrade
AnaptysBio, Inc. (ANAB) was downgraded to D- from D on 12/4/2020 due to a decline in the volatility index.
AnaptysBio, Inc. (ANAB) was downgraded to D- from D on 12/4/2020 due to a decline in the volatility index.
D
Sell
11/18/2020Upgraded
AnaptysBio, Inc. (ANAB) was upgraded to D from D- on 11/18/2020 due to a noticeable increase in the growth index. Operating cash flow increased 13.24% from -$19.61M to -$17.01M.
AnaptysBio, Inc. (ANAB) was upgraded to D from D- on 11/18/2020 due to a noticeable increase in the growth index. Operating cash flow increased 13.24% from -$19.61M to -$17.01M.
D
Sell
8/11/2020Downgrade
AnaptysBio, Inc. (ANAB) was downgraded to D- from D on 8/11/2020 due to a large decline in the efficiency index, total return index and solvency index. Net income declined 160.81% from -$8.26M to -$21.55M, and total capital declined 5.09% from $401.88M to $381.44M.
AnaptysBio, Inc. (ANAB) was downgraded to D- from D on 8/11/2020 due to a large decline in the efficiency index, total return index and solvency index. Net income declined 160.81% from -$8.26M to -$21.55M, and total capital declined 5.09% from $401.88M to $381.44M.
D
Sell
12/17/2019Upgraded
AnaptysBio, Inc. (ANAB) was upgraded to D from D- on 12/17/2019 due to an increase in the volatility index and valuation index.
AnaptysBio, Inc. (ANAB) was upgraded to D from D- on 12/17/2019 due to an increase in the volatility index and valuation index.
D
Sell
11/19/2019Downgrade
AnaptysBio, Inc. (ANAB) was downgraded to D- from D on 11/19/2019 due to a substantial decline in the total return index, growth index and volatility index. Operating cash flow declined 42.4% from -$15.52M to -$22.1M, earnings per share declined from -$0.8866 to -$1.1469, and EBIT declined 26.59% from -$26.66M to -$33.75M.
AnaptysBio, Inc. (ANAB) was downgraded to D- from D on 11/19/2019 due to a substantial decline in the total return index, growth index and volatility index. Operating cash flow declined 42.4% from -$15.52M to -$22.1M, earnings per share declined from -$0.8866 to -$1.1469, and EBIT declined 26.59% from -$26.66M to -$33.75M.
D
Sell
10/23/2018Downgrade
AnaptysBio, Inc. (ANAB) was downgraded to D from D+ on 10/23/2018 due to a decline in the total return index.
AnaptysBio, Inc. (ANAB) was downgraded to D from D+ on 10/23/2018 due to a decline in the total return index.
D
Sell
10/8/2018Upgraded
AnaptysBio, Inc. (ANAB) was upgraded to D+ from D on 10/8/2018 due to a large increase in the total return index and growth index. Operating cash flow increased 28.85% from -$12.48M to -$8.88M, earnings per share increased from -$0.6338 to -$0.569, and EBIT increased 8.52% from -$15.76M to -$14.42M.
AnaptysBio, Inc. (ANAB) was upgraded to D+ from D on 10/8/2018 due to a large increase in the total return index and growth index. Operating cash flow increased 28.85% from -$12.48M to -$8.88M, earnings per share increased from -$0.6338 to -$0.569, and EBIT increased 8.52% from -$15.76M to -$14.42M.
D
Sell
5/10/2018Downgrade
AnaptysBio, Inc. (ANAB) was downgraded to D from D+ on 5/10/2018 due to a large decline in the growth index, total return index and solvency index. Operating cash flow declined 159.42% from -$4.81M to -$12.48M, EBIT declined 120.35% from -$7.15M to -$15.76M, and earnings per share declined from -$0.2997 to -$0.6338.
AnaptysBio, Inc. (ANAB) was downgraded to D from D+ on 5/10/2018 due to a large decline in the growth index, total return index and solvency index. Operating cash flow declined 159.42% from -$4.81M to -$12.48M, EBIT declined 120.35% from -$7.15M to -$15.76M, and earnings per share declined from -$0.2997 to -$0.6338.
D
Sell
3/21/2018Downgrade
AnaptysBio, Inc. (ANAB) was downgraded to D+ from C- on 3/21/2018 due to a decline in the valuation index and total return index.
AnaptysBio, Inc. (ANAB) was downgraded to D+ from C- on 3/21/2018 due to a decline in the valuation index and total return index.
C
Hold
3/6/2018Upgraded
AnaptysBio, Inc. (ANAB) was upgraded to C- from D on 3/6/2018 due to a major increase in the growth index, valuation index and efficiency index. Total capital increased 178.5% from $115.62M to $322.01M, earnings per share increased from -$0.45 to -$0.2993, and net income increased 24.52% from -$9.09M to -$6.86M.
AnaptysBio, Inc. (ANAB) was upgraded to C- from D on 3/6/2018 due to a major increase in the growth index, valuation index and efficiency index. Total capital increased 178.5% from $115.62M to $322.01M, earnings per share increased from -$0.45 to -$0.2993, and net income increased 24.52% from -$9.09M to -$6.86M.
D
Sell
2/1/2018Downgrade
AnaptysBio, Inc. (ANAB) was downgraded to D from D+ on 2/1/2018 due to a decline in the total return index and valuation index.
AnaptysBio, Inc. (ANAB) was downgraded to D from D+ on 2/1/2018 due to a decline in the total return index and valuation index.
D
Sell
12/8/2017Upgraded
AnaptysBio, Inc. (ANAB) was upgraded to D+ from D on 12/8/2017 due to an increase in the total return index.
AnaptysBio, Inc. (ANAB) was upgraded to D+ from D on 12/8/2017 due to an increase in the total return index.
D
Sell
11/9/2017Downgrade
AnaptysBio, Inc. (ANAB) was downgraded to D from D+ on 11/9/2017 due to a noticeable decline in the growth index, efficiency index and solvency index. EBIT declined 255.66% from -$2.56M to -$9.09M, earnings per share declined from -$0.1324 to -$0.45, and net income declined 238.67% from -$2.68M to -$9.09M.
AnaptysBio, Inc. (ANAB) was downgraded to D from D+ on 11/9/2017 due to a noticeable decline in the growth index, efficiency index and solvency index. EBIT declined 255.66% from -$2.56M to -$9.09M, earnings per share declined from -$0.1324 to -$0.45, and net income declined 238.67% from -$2.68M to -$9.09M.
D
Sell
10/10/2017Upgraded
AnaptysBio, Inc. (ANAB) was upgraded to D+ from D- on 10/10/2017 due to an increase in the total return index.
AnaptysBio, Inc. (ANAB) was upgraded to D+ from D- on 10/10/2017 due to an increase in the total return index.
D
Sell
10/2/2017Upgraded
AnaptysBio, Inc. (ANAB) was upgraded to D- from E+ on 10/2/2017 due to a large increase in the solvency index and total return index.
AnaptysBio, Inc. (ANAB) was upgraded to D- from E+ on 10/2/2017 due to a large increase in the solvency index and total return index.
E
Sell
7/5/2017Upgraded
AnaptysBio, Inc. (ANAB) was upgraded to E+ from E on 7/5/2017 due to a major increase in the total return index, solvency index and growth index. Earnings per share increased from -$1.6134 to -$0.7476, and the quick ratio increased from 9.91 to 13.35.
AnaptysBio, Inc. (ANAB) was upgraded to E+ from E on 7/5/2017 due to a major increase in the total return index, solvency index and growth index. Earnings per share increased from -$1.6134 to -$0.7476, and the quick ratio increased from 9.91 to 13.35.
E
Sell
4/21/2017None
AnaptysBio, Inc. (ANAB) was downgraded to E from U on 04/21/2017.
AnaptysBio, Inc. (ANAB) was downgraded to E from U on 04/21/2017.
NASDAQ
04/04/2025 12:57PM Eastern
Quotes delayed
